SmartPill Aims To Address Quality-Of-Life GI Disorders With SmartPill Capsule
This article was originally published in The Gray Sheet
SmartPill Diagnostics, Inc. will conduct a 100-patient, five-center clinical trial to support a 510(k) application for its SmartPill Capsule ingestible diagnostic for gastrointestinal disorders
You may also be interested in...
Johnson & Johnson's Ethicon Endo-Surgery unit will market Given Imaging's M2A Esophageal Capsule to gastro-esophageal reflux disorder (GERD) patients and their primary care physicians under an exclusive sales and co-marketing deal
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.